Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: Current evidence, persistent uncertainties, and future perspectives

doi:10.3748/wjg.118763

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 30

This Article

(22)

(18)

(0)

(512)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 14, 2026; 32(30): 118763
Published online Aug 14, 2026. doi: 10.3748/wjg.118763

Table 2 Ongoing phase III randomized controlled trials of prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer

Trial name	Registration number	Eligible population	Intervention	Primary endpoint	Estimated completion	Region
D2 resection and HIPEC in locally advanced gastric carcinoma (GASTRICHIP)	NCT01882933	Locally advanced gastric cancer (T3/T4/N+ or positive peritoneal cytology)	D2 gastrectomy ± HIPEC (oxaliplatin)	OS	May 2026	France
Efficacy of HIPEC in the treatment of locally advanced gastric cancer after radical gastrectomy with D2 (EHTLAGCRGD2)	NCT02356276	Locally advanced gastric cancer (cT3/T4, Nx, M0)	Surgery + systemic chemotherapy ± repeated paclitaxel HIPEC	5-year OS	January 2022	China
Prophylactic surgery plus HIPEC with CO₂ in patients affected by gastric carcinoma (GOETH study)	NCT03917173	High-risk gastric cancer (T3/T4/N+ or positive peritoneal cytology)	Radical gastrectomy ± HIPEC with CO₂ (mitomycin C + cisplatin)	DFS	June 2025	Italy
HIPEC + FLOT vs FLOT alone in patients with gastric cancer and GEJ (PREVENT)	NCT04447352	Resectable locally advanced gastric/gastroesophageal junction cancer (≥ cT3 any N)	Perioperative FLOT ± prophylactic HIPEC	PFS/DFS	May 2027	Germany
Laparoscopic gastrectomy with D2 lymphadenectomy combined with HIPEC or not	NCT05871099	Patients with locally advanced gastric cancer undergoing laparoscopic D2 radical gastrectomy	Laparoscopic (robotic) D2 surgery + HIPEC (2 times) + systemic ± prophylactic HIPEC	5-year RFS	December 2030	China

HIPEC: Hyperthermic intraperitoneal chemotherapy; OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; RFS: Recurrence-free survival; GEJ: Gastroesophageal junction.

Full Size Table

Citation: Cheng ZW, Liang YZ, Wei M, Yan ZB, Sun GR, Cui XH, Yu WB. Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: Current evidence, persistent uncertainties, and future perspectives. World J Gastroenterol 2026; 32(30): 118763
URL: https://www.wjgnet.com/1007-9327/full/v32/i30/118763.htm
DOI: https://dx.doi.org/10.3748/wjg.118763

Cheng ZW, Liang YZ, Wei M, Yan ZB, Sun GR, Cui XH, Yu WB. Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: Current evidence, persistent uncertainties, and future perspectives. World J Gastroenterol 2026; 32(30): 118763 [DOI: 10.3748/wjg.118763]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.